Li WF, Moi SH, Liu YW, Lin CC, Yong CC, Wang CC*, Yen YH*, Lin CY. A preoperative model to predict overall survival in patients with hepatoma undergoing resection. Am J Surg. 2024 Nov:237:115778. (SCI)
Yen YH*, Liu YW(co-first), Li WF, Yong CC, Wang CC*, Lin CY. A simple model to predict early recurrence of hepatocellular carcinoma after liver resection. Langenbecks Arch Surg. 2024 Aug 23;409(1):261. (SCI)
Yen YH*, Kuo FY(Co-first), Eng HL, Liu YW, Yong CC, Wang CC*, Li WF, Lin CY. Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes. Updates Surg. 2024 Jun;76(3):879-887. (SCI)
Yen YH*, Kee KM, Hu TH, Tsai MC, Kuo YH, Li WF, Liu YW, Wang CC*, Lin CY. Hepatitis B virus-related hepatocellular carcinoma has superior overall survival compared with other etiologies. PLoS One. 2024 Mar 15;19(3):e0290523. (SCI)
Li WF, Moi SH, Liu YW, Yong CC, Wang CC*, Yen YH*, Lin CY. Using the hazard function to evaluate hepatocellular carcinoma recurrence risk after curative resection. Updates Surg. 2023 Dec;75(8):2147-2155. (SCI)
Yen YH*, Kuo FY(Co-first), Eng HL, Liu YW, Yong CC, Li WF, Wang CC*, Lin CY. Tumor necrosis as a predictor of early tumor recurrence after resection in patients with hepatoma. PLoS One. 2023 Nov 16;18(11):e0292144. (SCI)
Yen YH*, Li WF(Co-first), Liu YW, Yong CC, Wang CC*, Lin CY. A simple preoperative model to predict overall survival of patients undergoing liver resection for hepatocellular carcinoma ≧10 cm. HPB (Oxford). 2023 Nov;25(11):1373-1381. (SCI)
Liu YW, Moi SH, Li WF, Lin CC, Yong CC, Wang CC*, Yen YH*, Lin CY. A preoperative model for predicting early recurrence in patients undergoing resection for single hepatocellular carcinoma. Eur J Surg Oncol. 2023 Aug;49(8):1444-1449. (非SCI)
Li WF, Liu YW, Wang CC*, Yong CC, Lin CC, Yen YH*. Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver Cancer stages. Langenbecks Arch Surg. 2023 May 1;408(1):169. (SCI)
Liu YW, Li WF, Kuo FY, Eng HL, Wang CC*, Lin CC, Yong CC, Yen YH*. Overall survival among patients who undergo resection does not differ significantly between T1a and T1b hepatocellular carcinoma based on the 8th American Joint Commission on Cancer. Langenbecks Arch Surg. 2023 Apr 27;408(1):166. (SCI)
Yen YH*, Kee KM, Li WF, Liu YW, Wang CC*, Hu TH, Tsai MC, Kuo YH, Lin CY. Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. Cancers (Basel). 2023 Mar 9;15(6):1687. (SCI)
Kuo FY, Eng HL, Li WF, Liu YW, Wang CC*, Lin CC, Yong CC, Yen YH*. Tumor Necrosis Is an Indicator of Poor Prognosis Among Hepatoma Patients Undergoing Resection. J Surg Res. 2023 Mar;283:1091-1099. (SCI)
Li WF, Liu YW, Wang CC*, Yong CC, Lin CC, Yen YH*. Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of ≦ 2 cm. PLoS One. 2023 Feb 9;18(2):e0281154. (SCI)
Yen YH*, Liu YW, Li WF, Wang CC*, Yong CC, Lin CC, Lin CY. Alpha-Fetoprotein Combined with Radiographic Tumor Burden Score to Predict Overall Survival after Liver Resection in Hepatocellular Carcinoma. Cancers. 2023 Feb;15(4):1203. (SCI)
Yen YH*, Kee KM, Li WF, Liu YW, Wang CC*, Hu TH, Tsai MC, Lin CY. Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. Cancers. 2023 Feb;15(4):1222. (SCI)
Yen YH*, Li WF, Kee KM, Wang CC*, Cheng YF, Lu SN, Hung CH, Liu YW, Hu TH. Seven centimeters as an optimal cutoff value for prognosis stratification in large monofocal hepatocellular carcinoma. Langenbecks Arch Surg. 2023 Jan 7;408(1):12. (SCI)
Li WF, Yen YH*(co-first), Liu YW, Wang CC*, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg. 2022 Aug;74(4):1345-1352. (SCI)
Li WF, Yen YH*(co-first), Liu YW, Wang CC*, Yong CC, Lin CC. Preoperative predictors of non-transplantable recurrence after resection for early-stage hepatocellular carcinoma: application in an East Asian cohort. Updates Surg. 2022 Jun;74(3):891-897. (SCI)
Liu YW, Yen YH*(co-first), Li WF, Wang CC*, Lu SN, Kee KM, Yong CC, Cheng YF, Wang JH, Hu TH, Hung CH, Chen CH. Minimally invasive surgery versus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma: Results from a high-volume liver surgery center in East Asia. Surg Oncol. 2022 Jun;42:101769. (SCI)
Li WF, Yen YH*(co-first), Liu YW, Wang CC*, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg. 2022 May;223(5):945-950. (SCI)
Yen YH*, Li WF(co-first), Kee KM, Wang CC*, Cheng YF, Wang JH, Lu SN, Hung CH. The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. Langenbecks Arch Surg. 2022 Feb;407(1):225-234. (SCI)
Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY*, Cheng YF, Wang JH, Yen YH*, Liu TT, Li WF, Chen CH. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg. 2022 Feb;223(2):339-345. (SCI)
Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*. Liver resection in elderly patients with hepatocellular carcinoma: age does matter. Updates Surg. 2021 Aug;73(4):1371-1380. (SCI)
Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*. Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival. Updates Surg. 2021 Apr;73(2):399-409. (SCI)
Yen YH*, Cheng YF, Wang JH, Lin CC, Chen CH, Wang CC. Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias. PLoS One. 2021 Mar 25;16(3):e0249194. (SCI)
Yen YH*, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS One. 2021 Jan 13;16(1): e0244939. (SCI)
Kuo FY, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*. Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. J Surg Oncol. 2021 Jan;123(1):222-235. (SCI)
Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH*, Chen CH. Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. J Surg Oncol. 2020 Dec ;122(8):1587-1594. (SCI)
Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Wang JH, Yen YH*. Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center. PLoS One. 2020 Mar 27;15(3):e0230897. (SCI)
Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, Liu YW, Cheng JY, Chen CH, Hu TH*. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLoS One. 2020 Mar 12;15(3):e0230005. (SCI)
Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, Hu TH*. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS One. 2019 Oct 3;14(10):e0222605. (SCI)
Yen YH, Kuo FY, Chen CH, Hu TH*, Lu SN, Wang JH, Hung CH. Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice. Medicine (Baltimore). 2019 Jul;98(27):e16270. (SCI)
Yen YH, Hu TH*. Reply to the Letter to the Editor regarding Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease: More questions than answer? J Formos Med Assoc. 2019 Jan;118(1 Pt 3):537-538. (SCI)
Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Dig Liver Dis. 2019 Jan;51(1):142-148. (SCI)
Yen YH, Kee KM, Chen CH, Hu TH*, Lu SN, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS One. 2019 Jan 9;14(1):e0208858. (SCI)
Yen YH, Kuo FY, Lin CC, Chen CL, Chang KC, Tsai MC, Hu TH*. Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter. Transplant Proc. 2018 Dec;50(10):3533-3538. (SCI)
Yen YH, Kee KM, Kuo FY, Chang KC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort. Medicine (Baltimore). 2018 Dec;97(50):e13383. (SCI)
Yen YH, Tsai MC, Wu CK, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tseng PL, Lin MT, Huang CM, Lin JT, Hu TH*. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. J Formos Med Assoc. 2018 Sep;117(9):833-840. (SCI)
Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018 Jun 28;13(6):e0199760. doi: 10.1371/journal.pone.0199760.
Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, Wu CK, Lin JT, Hu TH*, Lu SN, Wang JH, Hung CH, Chen CH. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int. 2018 Jun;38(6):1064-1073. (SCI)
Yen YH, Hu TH*. Reply to the letters to the editor regarding the elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease: Methodological issues. J Formos Med Assoc. 2018 Apr;117(4):352.
Yen YH, Chang KC, Tsai MC, Tseng PL, Lin MT, Wu CK, Lin JT, Hu TH*, Wang JH, Chen CH. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. J Formos Med Assoc. 2018 Apr;117(4):268-275.
Yen YH, Chen JF, Wu CK, Lin MT, Chang KC, Tseng PL, Tsai MC, Lin JT, Hu TH*. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. J Formos Med Assoc. 2017 Nov;116(11):852-861. (SCI)
Huang CM, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tsai MC, Tseng PL, Lin MT, Wu CK, Hu TH, Cho CL, Yen YH*. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PLoS One. 2017 Aug 10;12(8):e0182204. (SCI)
Yen YH, Chen JB*, Cheng BC, Chen JF, Chang KC, Tseng PL, Wu CK, Tsai MC, Lin MT, Hu TH*. Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study. PLoS One. 2017 Apr 20;12(4):e0176027. (SCI)
Cheng BC#, Yen YH#(co-first), Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, Lin MT, Lin JT, Chen JB*, Hu TH*. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep. 2017 Apr 19;7:46458. (SCI)
Yen YH, Huang CM, Wei KL, Wang JH, Lu SN, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH*. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep. 2016 Sep 26;6:33816.
Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH*. Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. BMC Gastroenterol. 2016 Jul 25;16(1):73. (SCI)
Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH*. Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients. J Formos Med Assoc. 2016 Jun;115(6):440-4. (SCI)
Yen YH, Wang JC, Hung CH, Lu SN, Wang JH, Hu TH, Kee KM, Hsiao CC*, Lee CM*. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. J Formos Med Assoc. 2015 Jul;114(7):652-8. (SCI)
Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, Lee CM, Lin CY, Wang CC, Chen TY, Huang YJ, Lu SN*. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009 Jun;41(6):431-41. (SCI)
Yen YH, Hung CH, Hu TH, Chen CH, Wu CM, Wang JH, Lu SN, Lee CM*. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008 Jan 1;27(1):72-9. (SCI)
Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int. 2007 Dec;27(10):1349-55. (SCI)
Yen YH, Wang JH, Lu SN, Chen TY, Changchien CS, Chen CH, Hung CH, Lee CM. Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia. Eur J Radiol. 2006 Dec;60(3):439-44. (SCI)
Yen YH, Wang JH, Hung CH, Chen CH, Tseng PL, Lu SN. Gastric ulcer triggered after percutaneous ethanol injection therapy for left lobe hepatocellular carcinoma. Liver Int. 2006 May;26(4):502-3. (SCI)
Yen YH, Chen CH, Wang JH, Lee CM, Changchien CS, Lu SN. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int. 2005 Dec;25(6):1162-8. (SCI)
Yen YH, Wang JH, Lu SN, Changchien CS. Contrast-enhanced ultrasonography in hepatic angiomyolipoma. J Ultrasound Med. 2005 Jun;24(6):855-9. (SCI)
